rosiglitazone has been researched along with 2'-hydroxy-4-methoxychalcone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, FR; Chuang, DW; El-Shazly, M; Hsieh, CT; Hsieh, TJ; Tsai, YH; Wu, SF; Wu, YC; Yen, CT | 1 |
| Chang, CC; Chang, FR; Chang, WC; Du, YC; Hsieh, TJ; Liu, CS; Wu, YC | 1 |
2 other study(ies) available for rosiglitazone and 2'-hydroxy-4-methoxychalcone
| Article | Year |
|---|---|
Synthesis of chalcone derivatives as potential anti-diabetic agents.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Biological Transport, Active; Chalcones; Diabetes Mellitus; Glucose; Humans; Hypoglycemic Agents; Mice; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones | 2012 |
2-hydroxy-4'-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma.
Topics: Aorta; Atherosclerosis; Cell Cycle; Cell Proliferation; Chalcones; Drug Synergism; Gene Expression Regulation; Humans; Inflammation; Lipoproteins, LDL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2012 |